> top > docs > PMC:7696151 > spans > 90544-92439 > annotations

PMC:7696151 / 90544-92439 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
2744 1112-1115 Gene denotes DCX Gene:1641
2745 1166-1169 Gene denotes DCX Gene:1641
2746 1312-1315 Gene denotes DCX Gene:1641
2747 1604-1607 Gene denotes DCX Gene:1641
2748 19-30 Species denotes T. whipplei Tax:2039
2749 116-127 Species denotes T. whipplei Tax:2039
2750 135-140 Species denotes human Tax:9606
2751 509-517 Species denotes patients Tax:9606
2752 668-679 Species denotes T. whipplei Tax:2039
2753 1040-1051 Species denotes C. burnetii Tax:777
2754 1123-1134 Species denotes T. whipplei Tax:2039
2755 1186-1197 Species denotes T. whipplei Tax:2039
2756 1341-1349 Species denotes patients Tax:9606
2757 710-743 Chemical denotes trimethoprim and sulfamethoxazole
2758 835-847 Chemical denotes trimethoprim MESH:D014295
2759 892-908 Chemical denotes sulfamethoxazole MESH:D013420
2760 1116-1119 Chemical denotes HCQ MESH:D006886
2761 1331-1334 Chemical denotes HCQ MESH:D006886
2762 1583-1586 Chemical denotes HCQ MESH:D006886
2763 1694-1697 Chemical denotes DXC MESH:D004318
2764 1766-1777 Chemical denotes ceftriaxone MESH:D002443
2765 76-93 Disease denotes Whipple’s disease MESH:D008061
2766 265-274 Disease denotes infection MESH:D007239
2767 338-346 Disease denotes diarrhea MESH:D003967
2768 363-376 Disease denotes malabsorption MESH:D008286
2769 382-393 Disease denotes weight loss MESH:D015431
2770 413-426 Disease denotes Joint disease MESH:D007592
2771 555-572 Disease denotes cardiac disorders MESH:D006331
2772 612-629 Disease denotes Whipple’s disease MESH:D008061
2773 1052-1062 Disease denotes infections MESH:D007239

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T237 338-346 Phenotype denotes diarrhea http://purl.obolibrary.org/obo/HP_0002014
T238 363-376 Phenotype denotes malabsorption http://purl.obolibrary.org/obo/HP_0002024
T239 382-393 Phenotype denotes weight loss http://purl.obolibrary.org/obo/HP_0001824
T240 413-426 Phenotype denotes Joint disease http://purl.obolibrary.org/obo/HP_0001367

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T576 0-94 Sentence denotes On the other hand, T. whipplei is a Gram-positive bacterium responsible for Whipple’s disease.
T577 95-249 Sentence denotes The natural niche of T. whipplei is the human intestine since, in the intestinal mucosa, the bacterium is taken by macrophages, where it replicates [147].
T578 250-412 Sentence denotes This bacterial infection is primally characterized by digestive tract disorders such as diarrhea (75% of cases), malabsorption, and weight loss (80–90% of cases).
T579 413-524 Sentence denotes Joint disease may appear more than six years before the diagnosis and occur in more than 80% of patients [148].
T580 525-630 Sentence denotes Furthermore, neurological and cardiac disorders can also be frequently associated with Whipple’s disease.
T581 631-791 Sentence denotes For years the standard treatment for T. whipplei has included a combination of trimethoprim and sulfamethoxazole; however, relapses were not uncommon [149,150].
T582 792-1001 Sentence denotes Later, in vitro studies, demonstrated that trimethoprim was inactive on this bacterium [154], while sulfamethoxazole induced bacterial resistance, making the co-administration completely ineffective [154,156].
T583 1002-1165 Sentence denotes Based on the good results of treating C. burnetii infections, it was decided to test in vitro the association DCX/HCQ on T. whipplei, obtaining good results [154].
T584 1166-1255 Sentence denotes DCX/HCQ efficacy on T. whipplei diseases was demonstrated in a clinical trial dated 2014.
T585 1256-1473 Sentence denotes This study showed that the administration of 200 mg/day DCX and 600 mg/day HCQ to 13 patients results in better outcomes (0/13 failures) even after 1 year of treatment, compared to standard antibiotics regimens [155].
T586 1474-1723 Sentence denotes To date, several case reports available in the literature supported a therapy consisting of a combination of HCQ (600 mg/day) and DCX (200 mg/day) for a lifetime or at least one year, followed by a maintenance dosage of DXC used alone [156,157,158].
T587 1724-1895 Sentence denotes In some cases, prophylaxis of intravenous ceftriaxone (2g/day) for the first two weeks followed by HCQ/DXC for at least 12–18 months has been recommended [72,159,160,161].